Evidence map›Paper›PMID 30558580›Full record

ArticleBMC immunology2018

Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia.

Gizachew Ayele, Belay Tessema, Anteneh Amsalu, Getachew Ferede, Gizachew Yismaw

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gizachew AyeleCollege of Health Sciences, Mizan-Tepi University, P.O. BoX 206, Mizan Teferi, Ethiopia. ayele.gizachew@yahoo.com.ORCID 0000-0002-7666-3375
Belay TessemaDeparthement of Medical Microbiology college of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Anteneh AmsaluDeparthement of Medical Microbiology college of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Getachew FeredeDeparthement of Medical Microbiology college of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Gizachew YismawDeparthement of Medical Microbiology college of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
University of Gondar · ETMizan Tepi University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe initiation of highly active antiretroviral therapy (HAART) plays a significant role in the clinical management of HIV infected people by preventing morbidity and mortality. This benefit becomes, the most terrible when treatment failure develops. Thus, this research aims to assess the prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia.

resultsPatients on ART with a minimum of 6 months and up to 12 years of treatment were being enrolled. The prevalence of treatment failure, immunological failure and virological failure among people living with HIV/AIDS attending University of Gondar referral hospital were 20.3, 13.2, and 14.7%, respectively. Patients who had no formal education (Adjusted odds ratio (AOR): 3.8; 95% CI, 1.05-13.77), primary level education (AOR: 4.2; 95% CI, 1.16-15.01) and duration on ART < 6 years (AOR: 2.1; 95%CI, 1.12-3.81) were a significant risk factor. However, initial adult regimen D4T +  3TC+ EFV (AOR: 0.025; 95% CI, 0.002-0.36), AZT +3TC + NVP (AOR: 0.07; 95% CI, 0.01-0.71), AZT +  3TC + EFV (AOR: 0.046; 95% CI, 0.004-0.57) andTDF+3TC + EFV (AOR: 0.04; 95% CI, 0.004-0.46) were significantly protective for treatment failure.

conclusionsTimely and early identification of associated factors and monitoring antiretroviral therapy treatment failure should be done to enhance the benefit and to prevent further complication of the patients. It is preferable to initiate ART using any one of the following ART regimens: AZT +3TC + NVP, AZT + 3TC + EFV and TDF + 3TC + EFV to prevent treatment failure. Since the prevalence of this treatment failure and its associated factor may be different from other ART centers and community in Ethiopia, further national representative institutional based cross-sectional researches are needed across all ART centers of Ethiopia in order to determine the prevalence of treatment failure and its associated factors.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentAdultAgedCD4-Positive T-LymphocytesCross-Sectional StudiesEthiopiaFemaleHIV InfectionsHumansMaleMiddle AgedPrevalenceReferral and ConsultationRetrospective StudiesTreatment FailureHIV/AIDsImmunological failureTreatment failureVirological failure

Identifiers

PMID30558580
PMCPMC6296084
OpenAlexW2904932625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.